This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

ENCORE POSTER
Key Characteristics of the Atypical Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Schizophrenia
Author(s):

Leslie Citrome,1 Christoph U. Correll,2-4 Gregory W. Mattingly,5 Andrew J. Cutler,6 Amber R. Hoberg,7 Peter J. Weiden,8 Bhaskar Rege,9 James A. McGrory,9 Martin Dunbar,9 Craig Hopkinson,9 David McDonnell10

1New York Medical College, Valhalla, NY, USA; 2Zucker Hillside Hospital, Glen Oaks, NY, USA; 3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 4Charité Universitätsmedizin, Berlin, Germany; 5St. Charles Psychiatric Associates, St. Charles, MO, USA; 6SUNY Upstate Medical University Hospital, Syracuse, NY, USA; 7WellMed Medical Management, South Texas Medical Center, San Antonio, TX, USA; 8Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; 9Alkermes, Inc., Waltham, MA, USA; 10Alkermes Pharma Ireland Ltd, Dublin, Ireland

Content available until 11/09/2025